logo-loader
viewMaxCyte Inc

MaxCyte to make five presentations before the year-end on groundbreaking CARMA system

The platform can rapidly produce cell therapies taking one day where traditional methods might take one to two weeks

MaxCyte -

MaxCyte Inc (LON:MXCT) said it is taking part in five industry conferences at which it will showcase its CARMA technology.

The platform can rapidly produce cell therapies taking one day where traditional methods might take one to two weeks.

It is used by some of the world’s largest drug companies, and CARMA is at the heart of around 70 clinical and pre-clinical programmes.

MaxCyte also used the system to develop its lead drug candidate, MCY-M11, which is currently in phase I trials with people suffering advanced ovarian cancer and peritoneal mesothelioma.

Below are the industry forums at which MaxCyte will present:

ESMO Congress 2019

27 September–1 October 2019, Barcelona, Spain

This is a poster later Monday (today) by Christina Annunziata looking at MCY-M11

Cell & Gene Meeting on the Mesa

2–4 October 2019, Carslbad, California

MaxCyte’s chief executive Doug Doerfler will present the CARMA pipeline on Wednesday, 2 October

BIO Investor Forum

22–23 October, San Francisco, California

Doerfler will present to attendees on the CARMA pipeline

Society for Immunotherapy of Cancer

6–10 November, National Harbor, MD

Director of technical operations, Robert Keefe, will present a poster titled: “Single-day CAR manufacturing platform using mRNA and Flow Electroporation Technology” on November 9

BIO-Europe 2019

11–13 November, Hamburg Germany

Doerfler will present to attendees on the CARMA pipeline

Quick facts: MaxCyte Inc

Price: 110 GBX

AIM:MXCT
Market: AIM
Market Cap: £63.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read